News

Enlarge image

FundingUK

Wellcome Trust invests a £200m VC

04.01.2013 - The Wellcome Trust’s new venture capital unit Syncona Partners LLC pours £200m into early stage healthcare start ups.

The world’s second largest charity plans to invest between £1m-£20m in each of its future portfolio companies as announced last spring. According to Wellcome's annual report last month, Syncona has already made one investment. The directly owned and managed investment firm combines the trust’s experience in the health and biotechnology sectors with its investment expertise. While Syncona offers a new source of finance and guidance for healthcare businesses at an early stage of their development, the trust hopes to make some return on investment to fuel its pipeline of charitable projects.

“We expect to play our part in building successful businesses based upon innovation within the life science and health-care industry,” Syncona Chief Executive Officer Martin Murphy said in a statement. According to the Trust’s annual report, its role is becoming an increasingly global one. It disclosed that UK assets now account for a mere 6% of its £14.5bn investment portfolio, down from 13% in 2009 and 33% in 2006. Hence the portfolio “has hardly suffered from the underperformance of European assets in the financial crisis.” The influential investor has also cut its assets in Europe, with the proportion of its portfolio invested in the continent falling to 13% (2009: 22%; 2006: 48%). The charity said that it envisaged better returns from faster-growing nations in Asia and Latin America.

© eurobiotechnews.eu/bk

http://www.european-biotechnology-news.com/news/news/2013-01/wellcome-trust-invests-a-pound200m-vc.html

ResearchEUUK

27.07.2016 In view of the Brexit, research academies across Britain are calling for a “bold commitment” from the government. The Royal Society President urges the UK government to underwrite the research of British scientists applying for EU funding.

FinancingBelgium

20.07.2016 Belgian molecular diagnostics company Biocartis Group NV has raised €55m and will use the funds mainly to expand manufacturing capacities for its PCR-based molecular diagnostics system Idylla.

Stock marketsFranceEU

19.07.2016 It is Europe’s first gene therapy company to float on Euronext: Gensight raised €40m in its IPO. And it is not the only French company that has taken the leap in an uncertain market climate – Alzheimer’s expert Pharnext also went public.

ResearchUK

18.07.2016 When NASA blasted off to the International Space Station on Monday morning, it had UK tech on board. A miniature DNA sequencer from Oxford Nanopore will be used to keep an eye on the ISS atmosphere – and may even analyse alien DNA one day.

M&AUKSwitzerland

13.07.2016 Cell Medica has acquired Swiss antibody specialist Delenex Therapeutics. The deal nets the British cellular therapeutics developer Delenex’ proprietory antibody fragment platform Pentrabody.

R&DAustriaFrance

12.07.2016 Vienna-based vaccine specialist Themis Bioscience GmbH has secured broad access to a promising virus vaccine vector tech by extending its license agreement with French Institut Pasteur. Its goal: to develop a Zika vaccine.

M&AFranceEU

07.07.2016 Californian biopharma Medivation has agreed to confidential negotiations with its suitors, in particular the French pharmaceutical company Sanofi, which aggressively has buffeted the cancer therapy specialist for months.

Prenatal DiagnosticsEUUK

06.07.2016 The European Commission started an investigation into Illumina’s and Sequenom’s 2014 patent agreement, UK-competitor Premaitha Health said. The two US companies had agreed to pool their Noninvasive Prenatal Testing IP.

GenericsSpainGermanyEU

04.07.2016 Cinfa Biotech is shuffling for position on the lucrative biosimilar market. The Spanish-German company has published positive results in a study for a pegfilgrastim copycat with 172 healthy volunteers in Germany.

Drug discoveryUKSwitzerland

30.06.2016 UK’s Heptares Therapeutics and Paul Scherrer Institute spinoff leadXpro will collaborate to find new approaches for the determination of high-res X-ray structures of G protein-coupled receptors to find new drugs.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • NEWRON (CH)18.50 CHF9.14%
  • GENMAB (DK)1210.00 DKK5.68%
  • VALNEVA (F)2.42 EUR5.68%

FLOP

  • KAROLINSKA (S)7.30 SEK-3.95%
  • BIOTIE THERAPEUTICS (FI)0.27 EUR-3.57%
  • SAREUM HOLDINGS (UK)0.60 GBP-3.23%

TOP

  • PROTHENA PLC (IE)51.61 USD42.6%
  • PHARMING (NL)0.25 EUR31.6%
  • ACTIVE BIOTECH (S)11.95 SEK29.2%

FLOP

  • MOLOGEN (D)1.80 EUR-37.9%
  • SANTHERA (CH)56.40 CHF-20.6%
  • EVOCUTIS (UK)0.04 GBP-20.0%

TOP

  • KARO BIO (S)31.10 SEK1906.5%
  • NICOX (F)11.17 EUR481.8%
  • SAREUM HOLDINGS (UK)0.60 GBP172.7%

FLOP

  • BB BIOTECH (D)44.69 EUR-84.5%
  • NEUROVIVE PHARMACEUTICAL AB (S)4.87 SEK-77.6%
  • EVOCUTIS (UK)0.04 GBP-76.5%

No liability assumed, Date: 27.07.2016